HSIC vs MDLN: fair value comparison
Henry Schein, Inc. and Medline Inc. · Updated 2026-10-19
MDLN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, HSIC currently ranks higher by quality score.
| HSIC | MDLN | |
|---|---|---|
| Verdict | Fairly valued | Awaiting full valuation |
| Last price | $84.01 | $35.96 |
| 12-month range | $62.32–$90.86 | $31.64–$49.99 |
| Rank by discount to fair value | #47 of 108 Healthcare | — |
| Rank by quality score | #210 of 301 Healthcare | #211 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: HSIC fair value analysis · MDLN fair value analysis